Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 221Polycystic Ovary Syndrome 36Endometrial Neoplasms 15Ovarian Neoplasms 13Infertility 11Neoplasm Metastasis 9Carcinoma, Intraductal, Noninfiltrating 7Fallopian Tube Neoplasms 6Neoplasms 5Breast Diseases 5Triple Negative Breast Neoplasms 4Osteoporosis 4Leiomyoma 4Infertility, Female 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Recurrence 3Obesity 3Breast Cancer Metastatic 3Anovulation 3Uterine Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Pain 2Leiomyosarcoma 2HR Positive HER2 Negative Advanced Breast Cancer 2

Interventions

palbociclib 2Letrozole 2Fulvestrant 2pyrotinib 1Trastuzumab 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Estrogen Receptor-positive Breast Cancer × Letrozole × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡